<h4>Objectives</h4>Current treatments for cognitive and neuropsychiatric symptoms in Alzheimer's disease and related dementias (ADRD), such as cholinesterase inhibitors (CEIs) and selective serotonin reuptake inhibitors (SSRIs), show inconsistent effectiveness, necessitating a personalized therapy approach. This evidence concerns the gene BCHE and Alzheimer disease.